Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

NCT02011113 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Pomalidomide
DRUG: Dexamethasone

Sponsor

Celgene Corporation